ROVI launches an initiative to develop solutions that improve sustained-release injectable drug delivery technologies
The LAI Challenge seeks innovative solutions in the field of sustained-release injectable drug delivery technologies that may help overcome obstacles in enhancing the efficiency of the healthcare system and the rational use of medicines.
The President of the Andalusian Government, Juan Manel Moreno, visits the new Rovi plant in Escúzar (Granada)
This new facility will double the production capacity of low molecular weight heparins.
ROVI, Càrniques Celrà and Grupo Costa announce the construction of a facility at the Industrial Logistics Platform in Fraga (Huesca) to produce compounds of high technological value.
ROVI has obtained the best ESG score from among the 458 companies evaluated in its pharmaceutical subindustry category.
EIB and ROVI are signing a EUR 50 million loan agreement in Madrid for research, development and innovation.